Anti-METH ch-mAb7F9

First Human Subject Dosed in Phase 1a Study of ch-mAb7F9

The first subjects have been successfully dosed in InterveXion’s Phase 1a clinical safety study of ch-mAb7F9 in healthy human volunteers. Expected enrollment is 40 subjects in this escalating dose protocol covering doses from 0.2-20 mg/kg. InterveXion expects to complete dosing by fall and have preliminary data in early 2013.

Comments are closed.